According to the new book by the renowned doctor Hedy Kindler, M. D., there are a large number of patients affected by peritoneal mesothelioma that have survived for a number of years. Aggressive treatments can produce a greater survival rate to 60 percent; however, up to 71 percent of the patients presented a tumor growth that does not allow to take advantage of the benefits of the treatment.
The therapies applied to treat peritoneal mesothelioma include:
Surgery to drain the accumulated fluid known as a paracentesis.
Chemotherapy (using drugs such as pemetrexed, or, occasionally, vinblastine and gemcitabine).
Radiation therapy is not commonly used to treat the cancer peritoneal mesothelioma.
The treatment that has had most significant advances is a specialized therapy known as chemotherapy hyperthermic intra-peritoneal (HIPEC, for its acronym in English). This therapy introduces drugs hot that affect the mesothelioma into the abdominal cavity. Traditional chemotherapy is delivered in drugs in the form of pills or intravenously, while the HIPEC is an application many more direct and powerful.
When this therapy is combined with surgery, HIPEC can produce a medium-term of life for patients affected with peritoneal mesothelioma close to 5 years. The combination can provide a safe and lasting cure palliative for the fluids that have accumulated in the abdominal cavity.
Some studies ensure that the results are given due to the young age of patients affected by peritoneal mesothelioma. Other studies suggest that there are a number of cases relatively high mesothelioma peritoneal benign and, consequently, the number of patients who respond well to therapy is extremely high. Whatever the reason, the life expectancy for this type of mesothelioma is increasing with the passing of the years and one can predict that it will continue to so due to the technological advances that are being made.